Oriol Mirallas
Overview
Explore the profile of Oriol Mirallas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirallas O, Martin-Cullell B, Navarro V, Vega K, Recuero-Borau J, Gomez-Puerto D, et al.
Lancet Reg Health Eur
. 2024 Nov;
46:101063.
PMID: 39529819
Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best...
2.
Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, et al.
Clin Cancer Res
. 2024 Apr;
30(14):2986-2995.
PMID: 38687597
Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular...
3.
Martin-Cullell B, Virgili A, Riera P, Fumagalli C, Mirallas O, Pelegrin F, et al.
Br J Surg
. 2024 Mar;
111(3).
PMID: 38488528
Background: Histopathological and molecular features have been proposed to hold prognostic information, but few have been validated. The aim of this retrospective study was to validate the Genetic And Morphological...
4.
Hernando-Calvo A, Vila-Casadesus M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, et al.
Med
. 2023 Aug;
4(10):710-727.e5.
PMID: 37572657
Background: Immunotherapy is effective, but current biomarkers for patient selection have proven modest sensitivity. Here, we developed VIGex, an optimized gene signature based on the expression level of 12 genes...
5.
Cuesta-Borras E, Salvans C, Arques O, Chicote I, Ramirez L, Cabellos L, et al.
Cell Rep
. 2023 Aug;
42(8):112927.
PMID: 37537841
Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to...
6.
Grau-Bejar J, Garcia-Duran C, Garcia-Illescas D, Mirallas O, Oaknin A
Ther Adv Med Oncol
. 2023 Apr;
15:17588359231163836.
PMID: 37007635
Cervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an...
7.
Hernando-Calvo A, Mirallas O, Marmolejo D, Saavedra O, Vieito M, Assaf Pastrana J, et al.
Oral Oncol
. 2023 Mar;
140:106364.
PMID: 36989964
Background: Beyond programmed death-ligand 1 (PD-L1) assessed by the combined positive score (CPS) and tumor mutational burden (TMB), no other biomarkers are approved for immunotherapy interventions. Here, we investigated whether...
8.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, et al.
Lancet Oncol
. 2023 Mar;
24(4):335-346.
PMID: 36898391
Background: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care....
9.
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macia-Rivas L, Arrazubi V, et al.
Ther Adv Med Oncol
. 2023 Mar;
15:17588359231157641.
PMID: 36895850
Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall...
10.
Tagliamento M, Gennari A, Lambertini M, Salazar R, Harbeck N, Del Mastro L, et al.
J Clin Oncol
. 2023 Jan;
41(15):2800-2814.
PMID: 36720089
Purpose: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active...